Jump to:
The licence for Glivec (imatinib) has been extended to include its use as an adjuvant post-surgery treatment in patients with KIT (CD117)-positive gastrointestinal stromal tumours (GIST) who are at significant risk of the cancer returning after surgery.
The recommended dose of Glivec for this new indication is 400mg once daily.
Further information: Novartis
There are currently no comments.
You must log in to comment on articles.
New users can register here free for full access.
Educational resource for the learning and teaching of the
GP curriculum
Cumulative list of products discontinued from the UK market
in 2010
Possible searches include drugs (by brand, generic ingredient or drug class), diseases and more.
A Haymarket Publication © 1957 – 2010
